Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Neoadjuvant Nivolumab in Patients with Glioblastoma Multiforme
2015-000442-39Phase 2Completed
- Sponsor
- Clínica Universidad de Navarra
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in glioblastoma (GBM), sponsored by Clínica Universidad de Navarra. Primary endpoint: Changes in CD8 and PD-L1 expression after one dose of nivolumab. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2015-000442-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000442-39.